Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 22

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 22
---
 was incorporated as a limited
liability company in Delaware on September 17, 2009. In October 2014, DiamiR entered into a Share Exchange Agreement with DiamiR,
LLC, pursuant to which DiamiR acquired 100% of the issued and outstanding units of DiamiR, LLC in exchange for 4,282,000 shares (100%)
of DiamiR’s common stock (the “Share Exchange”), and DiamiR, LLC became a wholly-owned subsidiary of DiamiR. The
Share Exchange was recognized as a combination of entities under common control as both DiamiR, LLC and DiamiR have been controlled before
and after the transaction by the same shareholders.

DiamiR has incurred net losses
in each year since its inception, including net losses of $743,235 and $614,405 for the years ended May 31, 2025 and 2024, respectively.
At May 31, 2025, DiamiR had an accumulated deficit of $5,822,571, primarily due to operating expenses. DiamiR has devoted most of its
financial resources to conducting studies on analysis of circulating organ-enriched miRNA biomarkers and building its patent portfolio.
DiamiR has not completed development of any product candidate and has therefore not generated any revenues from product sales. Because
of the numerous risks and uncertainties associated with the development of DiamiR’s LDTs, DiamiR is unable to accurately predict
the timing or amount of increased expenses or when, or if, DiamiR will be able to achieve or maintain profitability. DiamiR expects to
incur increased expenses as it conducts its clinical studies. DiamiR also expects an increase in its expenses associated with creating
additional infrastructure (including hiring additional personnel) to develop and launch CogniMIR and support operations.
As a result, DiamiR expects to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative
cash flows have had, and will continue to have, an adverse effect on DiamiR’s stockholders’ equity and working capital.

<div align='center'>5</div>

To date, DiamiR has financed
its operations through grant funding, including SBIR grants of approximately $9.7 million, an Alzheimer’s Drug Discovery Foundation
(ADDF) Award of $492,000, the sale of DiamiR equity securities to its founders in the total aggregate amount of $